Chapter 6

References

1. Willison HJ, Jacobs BC, van Doorn PA. (2016). Guillain-Barré syndrome. Lancet. 388(10045):717-27.
2. Toscano G, et al. (2020). Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 382(26):2574-6.
3. Hadden RD, et al. (1998). Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 44(5):780-8.
4. Nishimoto Y, Odaka M, Hirata K, Yuki N. (2004). Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol. 148(1-2):200-5.
5. Hughes RAC, et al. (2003). Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 61(6):736-40.
6. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. (2012). Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 78(13):1009-15.
7. Rajabally YA, Uncini A. (2012). Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 83(7):711-8.
8. “Guillain-Barré Syndrome Fact Sheet.” National Institute of Neurological Disorders and Stroke, 16 Mar. 2020. Available at: www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-sheets/Guillain-Barr%C3%A9-Syndrome-Fact-Sheet.
9. “Miller Fisher Syndrome Information Page: What research is being done?” National Institute of Neurological Disorders and Stroke, 27 Mar. 2019. Available at: www.ninds.nih.gov/Disorders/All-Disorders/Miller-Fisher-Syndrome-Information-Page.
10. “Guillain-Barré Syndrome.” Centers for Disease Control and Prevention, 20 Dec. 2019. Available at: www.cdc.gov/campylobacter/guillain-barre.html.